Abstract

Abstract

Friday, July 13, 2018

A breakthrough


Back on October 21, 2016, my blogpost topic was titled “A means to slow Alzheimer’s?” Some days earlier, I had seen an article by Damian Garde, who writes for the STAT news service, which covers
Alzheimer’s and 0ther neurological disorders. I was a bit tardy to understand the implications. As Garde noted at the time, a “secondary analysis of pooled data showed a 34 percent reduction in the patients’ cognitive decline.” But things didn’t go to fruition. And for the next couple of years, little progress was made in detecting  maddening Alzheimer’s secrets. My next sentence was an understatement: “This finding could be significant”—a sign that in 2016 my understanding of my disease was still rather shallow.
And then the breakthrough was revealed: Alzheimer’s gave up one of its cherished secrets. And it was Biogen, in Cambridge, which performed the alchemy, just after the 4th of July.
What does this mean for me and my cohorts? It’s complicated. My six-plus years of living with early-onset Alzheimer’s has brought me to the end of the first phase of the disease, and into the early-middle stage. In a statement, the company stated, “Biogen is declaring success with a once-failed treatment with for Alzheimer’s disease, pointing to positive secondary results in hopes of saving a drug that many had written off entirely.”
For those of us who are living with the disease, there are still Just organizing the far-flung clinical trials will be a vast organizing project. And, sadly, vast legions of people with Alzheimer’s too far down the Alzheimer’s path to qualify for the clinical trials. I myself am in good physical health, as I approach my 57th birthday. But I have a different concern: I may not be able to withstand the dosage to break up the amyloid plaque, which in recent years has emerged as the key aspect of Alzheimer’s disease.
As a high school football player and wrestler, I had a reputation for my toughness. The difference here is that I would be the passive object, worried that I wouldn’t be able to absorb the full strength of the dosage. Am I being irrational? It’s not like we are starting the clinical trials immediately. But in a-worst-case scenario, I could end up with brain inflammation, and leave me much more worse than I am now. Should I trust the odds? First of all, I want to know the odds.
The clinical trials are expected to last for two years on multiple continents. I invite my readers to contact me on this topic, at mitch.evich@gmail.com

8 comments:

  1. I'm honored to invite you to be a part of 11th International Conference on Vascular dementia, an independently organized Neurology event happening in February 15-16, 2019 at Amsterdam,Netherlands.we would like to honour you by inviting you to the position of plenary Speaker for Vascular Dementia 2019.Scientific Tracks and other informations: https://vasculardementia.conferenceseries.com/
    Email: dementiaconference18@gmail.com

    ReplyDelete
  2. This comment has been removed by a blog administrator.

    ReplyDelete
  3. This comment has been removed by a blog administrator.

    ReplyDelete
  4. This comment has been removed by a blog administrator.

    ReplyDelete
  5. This comment has been removed by a blog administrator.

    ReplyDelete
  6. This comment has been removed by a blog administrator.

    ReplyDelete
  7. This comment has been removed by a blog administrator.

    ReplyDelete
  8. Attention:

    Are you looking for a REAL FINANCIAL LOAN COMPANY to give you loan between 5,000 Euro and 5,000,000 Euro (for a business or company loan, personal loan, home loans, car loan, debt consolidation loans, venture capital, healthcare loan, etc.)
    Or have you been denied a loan from a bank or financial institution because of one reason or the other?
    Apply now and get real financial loan processed and approved within 3 days.
    MARK DAVSON FINANCIAL LOAN FIRM, we are an "Internationally Accredited Loan Lender" that give REAL FINANCIAL LOANS to individuals and companies in a low interest rate of 2% with your valid identity card or your country international passport for verification.
    Our loan Repayment starts 1 (One) year after you have received your loan, and repayment duration ranges from between 3 to 35 years duration.
    Our company also need a person that can be our company representative in your country.

    FOR IMMEDIATE RESPONSE AND PROCESSING OF YOUR LOAN REQUEST WITHIN 2 WORKING DAYS,
    Contact us directly through this email: markdavsonfinancialloanfirm@gmail.com

    Contact us with the following information:

    Full Name:____________________________
    Amount Needed as Loan:________________
    Loan Duration:_________________________
    Purpose for Loan:______________________
    Date of Birth:___________________________
    Gender:_______________________________
    Marital status:__________________________
    Contact Address:_______________________
    City/Zip code:__________________________
    Country:_______________________________
    Occupation:____________________________
    Mobile Phone:__________________________

    Send your request for immediate response to: markdavsonfinancialloanfirm@gmail.com

    Thank you
    C.E.O. Rev. Mark Davson
    MARK DAVSON FINANCIAL LOAN FIRM
    United Kingdom, England (UK)
    Email:markdavsonfinancialloanfirm@gmail.com
    Email: markdavsonloanfirm@hotmail.com
    Email: markdavsonloanlfirm@europe.com
    Website:http://davsonfinancialloanfirm.webs.com/
    Website:http://davsonfinancialloanfirmlatinoamerica.com/
    WhatsApp:+447404320361
    WhatsApp:+19046065496

    ReplyDelete